Results 151 to 160 of about 144,610 (311)

Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings

, 2013
Background: TNBC represents a heterogeneous subgroup of BC with poor prognosis and frequently resistant to CT. Material and methods: The relationship between Bcl2 immunohistochemical protein expression and clinicopathological outcomes was assessed in 736
Ball, G, Perry, C, Moseley, P, Madhusudan, S, Chan, SYT, Abdel-Fatah, TMA, Ellis, IO, Dickinson, P   +7 more
core   +1 more source

A microscopically assisted limited colectomy mouse model of early colon cancer

Animal Models and Experimental Medicine, EarlyView.
Establishment, surgery, and evaluation process of a microscope‐assisted limited colon resection mouse model for early‐stage colon cancer. Abstract Background Currently, there is a lack of an adequate rodent model for investigating surgical techniques and comprehensive treatment options for patients with colorectal cancer (CRC).
Yu Han, Yixin Zhang, Dazhi Gao, Xuefeng Zhao   +3 more
wiley   +1 more source

Gephyrin Neurological Autoimmunity

Annals of Neurology, EarlyView.
Gephyrin is a postsynaptic scaffold protein essential for inhibitory neurotransmission. Gephyrin‐immunoglobulin G (IgG) was reported, decades ago, in a single case of paraneoplastic stiff‐person‐like syndrome, but its broader clinical relevance remains unknown.
Maria Chiara Pantuliano, Friederike A. Arlt, Naomi Arenson, Irena Dujmovic Basuroski, Divyanshu Dubey, Connie E. Lesnick, John R. Mills, Sean J. Pittock, Anastasia Zekeridou, Michael A. Lane, Andrew McKeon   +10 more
wiley   +1 more source

Current Status of Neoadjuvant Treatment Before Surgery in High-Risk Localized Prostate Cancer

Localized high-risk (HR) prostate cancer (PCa) is a heterogeneous disease whose likelihood of a biochemical recurrence, metastatic progression and cancer-related mortality after initial treatment is higher when compared with patients with low (LR) or ...
Luis Enrique Ortega Polledo, Noelia Sanmamed Salgado, Dmitry Enikeev, Beatriz Gutiérrez Hidalgo, María Jesús Marugán Álvarez, Jesús Moreno Sierra, Bhaskar K. Somani, María Isabel Galante Romo, Javier Martín Monterrubio, Juan Gómez Rivas, Javier Puente Vázquez, Irene De La Parra Sánchez   +11 more
core   +1 more source

Plant Virus Immunotherapy for HPV‐Associated Oropharyngeal Squamous Cell Carcinoma

Advanced NanoBiomed Research, EarlyView.
Cowpea mosaic virus (CPMV) nanoparticles are safe and potent cancer immunotherapy candidates with strong immunomodulatory activity. CPMV activates innate immunity, which in turn drives adaptive immune responses and promotes durable, systemic antitumor effects.
Jessica Fernanda Affonso de Oliveira, Patrick Opdensteinen, Andrea Simms, Seongwon Jung, Giuliana P. Mognol, Hui Chen, Judith A. Varner, Nicole F. Steinmetz   +7 more
wiley   +1 more source

[Significance of neoadjuvant therapy before radical prostatectomy]

, 2004
Neoadjuvant therapy before radical prostatectomy should increase survival in patients. This is necessary especially in patients with adverse prognostic factors for locally advanced disease, because in this stage radical prostatectomy as the only ...
Paul, R;van Randenborgh, H;Kubler, H;Alschibaja, M;Hartung, R
core   +1 more source

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

British Journal of Clinical Pharmacology, EarlyView.
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi, Masato Ozaka, Naoki Sasahira, Yasuhiko Sakata, Yuki Kogure, Shinya Tamaki, Atsushi Wada, Yusuke Taki, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Masakazu Yamaguchi, Kenichi Suzuki   +21 more
wiley   +1 more source

Targeting treatment resistance: unveiling the potential of RNA methylation regulators and TG-101,209 in pan-cancer neoadjuvant therapy

Journal of Experimental & Clinical Cancer Research
Background Tumor recurrence and mortality rates remain challenging in cancer patients despite comprehensive treatment. Neoadjuvant chemotherapy and immunotherapy aim to eliminate residual tumor cells, reducing the risk of recurrence.
Yaoyao Zhou, Ziyun Liu, Cheng Gong, Jie Zhang, Jing Zhao, Xia Zhang, Xiangyu Liu, Bin Li, Rui Li, Zhenyu Shi, Yongjie Xie, Li Bao   +11 more
doaj   +1 more source

Anatomical Understanding and Evolution of Surgical Treatment for Cancer of the Esophagogastric Junction: From Anatomical Controversies to Precision Surgery

Gut Medicine, EarlyView.
ABSTRACT The incidence of cancer of the esophagogastric junction (EGJC) has surged globally. Historically, its unique anatomical position and dual histological characteristics generated significant controversy regarding tumor classification and surgical strategies.
Cien Sun, Hao Liu, Dehua Ma, William C. Cho, Pasan Witharana, Jianfei Shen   +5 more
wiley   +1 more source

Personalized Precision in Healthcare Payment Systems: Insights From a Real‐World Cancer Patients Cohort Study

Health Care Science, EarlyView.
We developed an effective prediction model for reasonably high hospitalization costs, using gastric cancer surgery patients as an example. Integrating this assessment into the healthcare payment system based on diagnosis‐related groups is expected to improve the individualization and precision of health insurance fund utilization.
Kan Xue, Hongrui Tian, Qi Wang, Yinkui Wang, Fei Shan, Yansui Yang, Miao Yu, Zhonghu He, Ziyu Li, Jiafu Ji   +9 more
wiley   +1 more source